Compare TGE & BEAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TGE | BEAT |
|---|---|---|
| Founded | 2023 | 2015 |
| Country | France | United States |
| Employees | 166 | 16 |
| Industry | Newspapers/Magazines | Retail: Computer Software & Peripheral Equipment |
| Sector | Consumer Discretionary | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 50.9M | 53.2M |
| IPO Year | N/A | N/A |
| Metric | TGE | BEAT |
|---|---|---|
| Price | $0.96 | $0.75 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $5.63 |
| AVG Volume (30 Days) | 23.4K | ★ 561.5K |
| Earning Date | 04-29-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $315.97 |
| P/E Ratio | $2.99 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.78 | $0.54 |
| 52 Week High | $10.33 | $4.00 |
| Indicator | TGE | BEAT |
|---|---|---|
| Relative Strength Index (RSI) | 41.61 | 30.59 |
| Support Level | $0.78 | $0.54 |
| Resistance Level | $1.22 | $0.94 |
| Average True Range (ATR) | 0.10 | 0.05 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 20.99 | 7.20 |
The Generation Essentials Group is a media and entertainment company. Its publications L'Officiel and The Art Newspaper publish print editions in a total of nearly 28 countries and territories and digital contents. It operate in the movie production sector having produced various Asia-focused movies. It operate in three operating segments: media and entertainment segment, hotel operations, hospitality and VIP services segment and strategic investment segment. Key revenue is generated from strategic investment segment that is engage in proprietary investments and management of portfolio, including listed and unlisted equity shares investments and movie income right investments.
HeartBeam Inc is a medical technology company focused on developing higher resolution ambulatory electrocardiogram (ECG) solutions that enable the detection and monitoring of cardiac disease outside a healthcare facility setting. The company's proprietary and patented technology platform captures the heart's electrical activity from three dimensions and synthesizes a 12-lead ECG from these signals. The company has received U.S. Food and Drug Administration (FDA) clearance for its ECG solutions.